Teladoc Health TDOC has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 8 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 1 | 4 | 5 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.5, a high estimate of $17.00, and a low estimate of $8.00. Experiencing a 34.38% decline, the current average is now lower than the previous average price target of $16.00.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Teladoc Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Elizabeth Anderson | Evercore ISI Group | Raises | In-Line | $9.00 | $8.00 |
| Glen Santangelo | Jefferies | Raises | Hold | $10.00 | $8.00 |
| Lisa Gill | JP Morgan | Lowers | Neutral | $9.00 | $16.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $10.00 | $10.00 |
| Jessica Tassan | Piper Sandler | Lowers | Overweight | $10.00 | $25.00 |
| George Hill | Deutsche Bank | Lowers | Hold | $10.00 | $15.00 |
| Jailendra Singh | Truist Securities | Lowers | Hold | $10.00 | $15.00 |
| Charles Rhyee | TD Cowen | Lowers | Hold | $9.00 | $15.00 |
| Sean Dodge | RBC Capital | Lowers | Outperform | $9.00 | $18.00 |
| Steve Valiquette | Barclays | Lowers | Overweight | $10.00 | $20.00 |
| David Grossman | Stifel | Lowers | Hold | $9.00 | $16.00 |
| Gil Luria | DA Davidson | Lowers | Neutral | $8.00 | $12.00 |
| Richard Close | Canaccord Genuity | Lowers | Buy | $17.00 | $25.00 |
| Michael Wiederhorn | Oppenheimer | Lowers | Outperform | $17.00 | $21.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Teladoc Health's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Teladoc Health analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Teladoc Health: A Closer Look
Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.
Teladoc Health: Financial Performance Dissected
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -1.53%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -130.39%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -44.19%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -21.36%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.06, caution is advised due to increased financial risk.
Analyst Ratings: What Are They?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
